Table 2.
Preoperative characteristics of patients undergoing robotic liver resection and intraoperative indocyanine green fluorescence
| Patients’ characteristics | Robotic liver resections n=76 |
|---|---|
| Age, years | 64.8 (20–84) |
| Sex (M), n (%) | 47 (61.8%) |
| BMI, kg/m2 | 26.2 ± 4.1 |
| ECOG/Karnofsky score | 0 (1–2)/90 (50–100) |
| CHILD, n (%)* | |
| A5 | 17 (65.4%) |
| A6 | 9 (34.6%) |
| MELD* | 8 (6–13) |
| Hepatopathy, n (%) | 26 (34.2%) |
| Viral | 16 (61.5%) |
| HCV | 11 (68.7%) |
| HBV | 5 (31.3%) |
| Alcoholic | 7 (26.9%) |
| Metabolic | 3 (11.5%) |
| Preoperative diagnosis, n (%) | |
| HCC | 26 (34.2%) |
| CRLM | 18 (23.7%) |
| CCC | 16 (21.1%) |
| Benign | 14 (18.4%) |
| Intrahepatic biliary lithiasis | 2 (2.6%) |
| Preoperative number of lesions | 117 |
| Lesions per patients | 1 (0–6)** |
| Malignant, n (%) | 102 (87.2%) |
| ASA score | 3 (1–3) |
| Charlson comorbidity index | 5.7 ± 2.8 |
| Platelets (×103 U/L) | 195 (68–559) |
| INR | 1.05 (0.89–1.3) |
| Total bilirubin (mg/dL) | 0.62 (0.10–2.59) |
| Albumin (g/dL) | 4.2 ± 0.55 |
| Creatinine (mg/dL) | 0.85 (0.59–1.58) |
| Previous abdominal surgery, n (%) | 44 (57.9%) |
| Previous liver surgery, n (%) | 9 (11.8%) |
| Previous chemotherapy, n (%)° | 16 (21.1%) |
BMI Body mass index; ECOG Eastern Cooperative Oncology Group; MELD model for end-stage liver disease; HCC hepatocellular carcinoma; CRLM colorectal liver metastases; CCC cholangiocarcinoma; ASA American Society of Anesthesiologists; INR international normalized ratio
*Calculated on 21 patients with hepatopathy
**Calculated on 59 patients, as two had no lesions and underwent liver resection for intrahepatic lithiasis
°Calculated on malignant indications only